首页> 外文OA文献 >Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

【2h】

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

机译：铂敏感复发性浆液癌患者的整体生存接受Olaparib维持单药治疗：从随机，安慰剂控制，双盲，第2期试验的更新分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jonathan A Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Philip Rowe; Elizabeth Lowe; Darren Hodgson; Mika A Sovak; Ursula Matulonis;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial [J] . Ledermann Jonathan A., Harter Philipp, Gourley Charlie, The lancet oncology . 2016,第11期

机译：接受olaparib维持单药治疗的铂敏感性复发性浆液性卵巢癌患者的整体生存：一项来自随机，安慰剂对照，双盲，2期试验的更新分析
2. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial (vol 18, pg 1274, 2017) [J] . Pujade-Lauraine E., Ledermann J. A., Selle F. The lancet oncology . 2017,第9期

机译：Olaparib片剂作为铂敏感，复发卵巢癌和BRCA1 / 2突变患者的维持治疗（SOLO2 / ENGOT-OV21）：双盲，随机，安慰剂控制，第3期试验（Vol 18，PG 1274， 2017）
3. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial [J] . Pujade-Lauraine Eric, Ledermann Jonathan A., Selle Frederic, The lancet oncology . 2017,第9期

机译：Olaparib片剂作为铂敏感，复发卵巢癌和BRCA1 / 2突变患者的维护治疗（SOLO2 / ENGOT-OV21）：双盲，随机，安慰剂控制，第3期试验
4. Phase I trial of motexafin-lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer [C] . Diana C. Stripp, Rosemarie Mick, Timothy C. Zhu, Conference on optical methods for tumor treatment and detection: Mechanisms and techniques in photodynamic therapy . 2004

机译：Matexafin-Lutetium介导的患者局部复发前列腺癌患者的术语I阶段试验
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Long-term efficacy tolerability and overall survival in patients with platinum-sensitive recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy [O] . Michael Friedlander, Ursula Matulonis, Charlie Gourley, 2018

机译：对铂敏感的复发性高级别浆液性卵巢癌患者的长期疗效耐受性和总生存率对化疗反应后接受维持性奥拉帕尼胶囊治疗
7. 235O Efficacy and safety of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (NORA) with individualized starting dose: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase III trial [O] . X. Wu, J. Zhu, R. Yin, 2020

机译：235O在中国铂敏感性复发性卵巢癌（Nora）中尼拉帕里布的疗效和安全性，具有个性化起始剂量：随机，双盲，安慰剂控制，III期试验的亚组分析

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

著录项

引文网络

相似文献

相关主题

期刊订阅